05:01 PM EDT, 05/14/2024 (MT Newswires) -- Enliven Therapeutics ( ELVN ) reported a Q1 loss late Tuesday of $0.54 per diluted share, narrower than the loss of $0.80 a year earlier.

Three analysts surveyed by Capital IQ expected a loss of $0.57.

As expected, no revenue for the quarter ended March 31 was reported.

As of March 31, the company said it had $320.5 million of cash, cash equivalents, and marketable securities, which is expected to provide a cash runway into late 2026.